These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 9696035

  • 1. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation.
    Giani C, Casalini P, Pupa SM, De Vecchi R, Ardini E, Colnaghi MI, Giordano A, Ménard S.
    Oncogene; 1998 Jul 30; 17(4):425-32. PubMed ID: 9696035
    [Abstract] [Full Text] [Related]

  • 2. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
    Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ.
    Cancer Res; 1999 Mar 15; 59(6):1347-55. PubMed ID: 10096569
    [Abstract] [Full Text] [Related]

  • 3. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
    Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D.
    Cancer Res; 2006 Apr 01; 66(7):3903-11. PubMed ID: 16585219
    [Abstract] [Full Text] [Related]

  • 4. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R.
    Int J Oncol; 2004 Mar 01; 24(3):591-608. PubMed ID: 14767544
    [Abstract] [Full Text] [Related]

  • 5. FGF signaling activates STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells.
    Johnson MR, Valentine C, Basilico C, Mansukhani A.
    Oncogene; 1998 May 01; 16(20):2647-56. PubMed ID: 9632141
    [Abstract] [Full Text] [Related]

  • 6. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
    Ethier SP, Kokeny KE, Ridings JW, Dilts CA.
    Cancer Res; 1996 Feb 15; 56(4):899-907. PubMed ID: 8631031
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin.
    Hwang MS, Yum YN, Joo JH, Kim S, Lee KK, Gee SW, Kang HI, Kim OH.
    Anticancer Res; 2001 Feb 15; 21(4A):2649-55. PubMed ID: 11724334
    [Abstract] [Full Text] [Related]

  • 8. Defects in p21WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells.
    Blagosklonny MV, Prabhu NS, El-Deiry WS.
    Cancer Res; 1997 Jan 15; 57(2):320-5. PubMed ID: 9000576
    [Abstract] [Full Text] [Related]

  • 9. C-erbB2, p27 and G1/S aberrations in human primary breast cancer.
    Lodén M, Perris F, Nielsen NH, Emdin SO, Landberg G.
    Anticancer Res; 2003 Jan 15; 23(3A):2053-61. PubMed ID: 12894578
    [Abstract] [Full Text] [Related]

  • 10. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME.
    Cancer Res; 2000 Jun 01; 60(11):3081-7. PubMed ID: 10850460
    [Abstract] [Full Text] [Related]

  • 11. Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells.
    Warrenfeltz SW, Lott SA, Palmer TM, Gray JC, Puett D.
    Mol Cancer Res; 2008 Nov 01; 6(11):1775-85. PubMed ID: 19010824
    [Abstract] [Full Text] [Related]

  • 12. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
    Menendez JA, Mehmi I, Lupu R.
    Int J Oncol; 2005 Mar 01; 26(3):649-59. PubMed ID: 15703820
    [Abstract] [Full Text] [Related]

  • 13. Overexpression of basic fibroblast growth factor in MCF-7 human breast cancer cells: lack of correlation between inhibition of cell growth and MAP kinase activation.
    Wieder R, Fenig E, Wang H, Wang Q, Paglin S, Menzel T, Gabrilove J, Fuks Z, Yahalom J.
    J Cell Physiol; 1998 Dec 01; 177(3):411-25. PubMed ID: 9808150
    [Abstract] [Full Text] [Related]

  • 14. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
    Ram TG, Schelling ME, Hosick HL.
    Cell Growth Differ; 2000 Mar 01; 11(3):173-83. PubMed ID: 10768865
    [Abstract] [Full Text] [Related]

  • 15. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
    Yang W, Klos KS, Zhou X, Yao J, Yang Y, Smith TL, Shi D, Yu D.
    Cancer; 2003 Sep 15; 98(6):1123-30. PubMed ID: 12973835
    [Abstract] [Full Text] [Related]

  • 16. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells.
    Mitchell KO, El-Deiry WS.
    Cell Growth Differ; 1999 Apr 15; 10(4):223-30. PubMed ID: 10319992
    [Abstract] [Full Text] [Related]

  • 17. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
    Soda G, Antonaci A, Bosco D, Nardoni S, Melis M.
    J Exp Clin Cancer Res; 1999 Sep 15; 18(3):363-7. PubMed ID: 10606183
    [Abstract] [Full Text] [Related]

  • 18. Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1.
    Chen C, Chang YC, Liu CL, Chang KJ, Guo IC.
    Breast Cancer Res Treat; 2006 Jul 15; 98(2):121-32. PubMed ID: 16752079
    [Abstract] [Full Text] [Related]

  • 19. Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells.
    Trost TM, Lausch EU, Fees SA, Schmitt S, Enklaar T, Reutzel D, Brixel LR, Schmidtke P, Maringer M, Schiffer IB, Heimerdinger CK, Hengstler JG, Fritz G, Bockamp EO, Prawitt D, Zabel BU, Spangenberg C.
    Cancer Res; 2005 Feb 01; 65(3):840-9. PubMed ID: 15705882
    [Abstract] [Full Text] [Related]

  • 20. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation.
    Aigner A, Juhl H, Malerczyk C, Tkybusch A, Benz CC, Czubayko F.
    Oncogene; 2001 Apr 19; 20(17):2101-11. PubMed ID: 11360194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.